司库奇尤单抗治疗银屑病至第5年的长期疗效与安全性:III期ERASURE和FIXTURE试验随机扩展研究结果
ERASURE和FIXTURE两项III期核心试验第1年达到PASI 75的应答者按2:1随机分配至原剂量持续治疗或安慰剂(停药),至第3年或复发;第1年部分应答者继续原剂量。第3年起全部开放标签。结果显示司库奇尤单抗疗效维持至第5年,生活质量持续改善,安全性与其他II/III期项目一致。
要点
- 第1年随机至安慰剂者多数复发,重新用药后应答快速恢复。
- 300 mg应答+部分应答组PASI 75/90/100从第1年86.8%/72.8%/45.9%至第3年82.3%/58.4%/32.7%,后稳定至第5年81.1%/62.8%/35.1%。
- 最常见不良事件为感染和侵染、鼻咽炎、上呼吸道感染;所有不良事件暴露调整发生率139.9(95%CI 130.3-149.9)。
核心结论
- 两项III期试验的4年扩展研究表明,司库奇尤单抗治疗至第5年仍有效并改善中重度斑块状银屑病患者的生活质量。
- 最常见不良事件为感染和侵染、鼻咽炎和上呼吸道感染,安全性特征与司库奇尤单抗II/III期临床开发项目一致。
研究设计与样本
- ERASURE和FIXTURE两项III期核心试验第1年(核心试验结束时)PASI 75应答者按2:1随机分配至原剂量(300或150 mg,持续治疗)或安慰剂(停药),每4周给药,直至第3年或复发(最大PASI较核心研究基线降低>50%)。
- 第1年部分应答者(达到PASI 50但未达PASI 75)继续核心试验原剂量。
- 第3年时全部患者接受开放标签司库奇尤单抗治疗,300 mg者继续原剂量,150 mg或安慰剂者由医生酌情给予150或300 mg。
- 研究注册于ClinicalTrials.gov,标识符NCT01544595。
主要发现
- 第1年随机至安慰剂者多数复发,但重新开始治疗后应答快速恢复。
- 300 mg应答+部分应答组第1年PASI 75/90/100为86.8%/72.8%/45.9%,至第3年降至82.3%/58.4%/32.7%,第4年83.3%/60.1%/32.2%,第5年81.1%/62.8%/35.1%。
- 皮肤病生活质量指数(DLQI)显示获益持续至第5年,绝对PASI应答在整个研究期间维持。
- 最常见不良事件为感染和侵染、鼻咽炎和上呼吸道感染(URTIs)。
- 所有不良事件的暴露调整发生率(EAIR;95%置信区间)为139.9(130.3-149.9);克罗恩病和中性粒细胞减少症的EAIR分别为0.1(0.0-0.3)和0.5(0.3-0.8)。
关键数值与推荐
- 第1年PASI 75应答者随机2:1至原剂量(300或150 mg)持续治疗或安慰剂停药。
- 第3年起全部患者接受开放标签司库奇尤单抗,300 mg者继续300 mg,150 mg或安慰剂者由医生酌情给予150或300 mg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the long-term extension study of the ERASURE and FIXTURE trials, the efficacy of secukinumab (a fully human anti-interleukin-17A monoclonal antibody) was demonstrated to have been maintained through to year 3 of treatment in moderate-to-severe plaque psoriasis. OBJECTIVES: To assess the efficacy and safety of secukinumab through to year 5 of treatment in moderate-to-severe plaque psoriasis. METHODS: Responders with ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) from two core trials - ERASURE and FIXTURE - were randomized 2 : 1 at year 1 (end of core trials) to either the same dose (300 or 150 mg, continuous treatment) or placebo (treatment withdrawal) every 4 weeks, until year 3 or relapse (> 50% reduction in maximal PASI from core study baseline). Partial responders (achieving PASI 50 but not PASI 75) at year 1 continued at the same dose as in the core trials. At year 3, all patients received open-label secukinumab treatment, with those on secukinumab 300 mg continuing on their dose, while those on secukinumab 150 mg or placebo received secukinumab 150 or 300 mg based on the physician's discretion. The study is registered on ClinicalTrials.gov with the identifier NCT01544595. RESULTS: Most patients randomized to placebo at year 1 relapsed, but the response was rapidly recaptured upon reinitiation of treatment. PASI responses were sustained with secukinumab through to year 5. The PASI responses for the 300 mg responders + partial responders group at year 1 (PASI 75/90/100: 86.8%/72.8%/45.9%) trended downwards until year 3 (PASI 75/90/100: 82.3%/58.4%/32.7%) and then remained stable through year 4 (PASI 75/90/100: 83.3%/60.1%/32.2%) until year 5 (PASI 75/90/100: 81.1%/62.8%/35.1%). Dermatology Life Quality Index showed sustained benefit up to year 5. Absolute PASI responses were maintained throughout the study. The most common adverse events (AEs) were infections and infestations, nasopharyngitis, and upper respiratory tract infections (URTIs). The overall exposure-adjusted incidence rate (EAIR; with 95% confidence interval) for all AEs was 139.9 (130.3-149.9). EAIRs for Crohn's disease and neutropenia were 0.1 (0.0-0.3) and 0.5 (0.3-0.8), respectively. CONCLUSIONS: The 4-year extension of two pivotal phase III trials demonstrated that secukinumab treatment was effective through to year 5 and improved quality of life in patients with moderate-to-severe plaque psoriasis. The most common AEs were infections and infestations, nasopharyngitis, and URTIs. The safety profile was consistent with that in the secukinumab phase II/III clinical development programme.
引用
- Langley RG, Sofen H, Dei-Cas I, et al. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2023. PMID: 36763857. doi:10.1093/bjd/ljac040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。